Some of these agents are currently being assessed in clinical trials (e.g., the SF3B1 inhibitor H3B-8800 in MDS, and the CLK inhibitor SM08502in solid tumours) [7]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.